FDA Approves Ziihera-Tislelizumab Combination: What the New First-Line Immunotherapy for HER2-Positive Gastroesophageal Cancer Actually Showed

What This Article Covers

On August 25, 2026, the FDA approved two new first-line treatment regimens built around zanidatamab-hrii (Ziihera), a dual-HER2-targeting bispecific antibody, for adults with HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma that can't be surgically removed or has spread. The approval is backed by statistically significant survival data from a large Phase 3 trial — a genuine step forward for a cancer type where the standard of care had gone essentially unchallenged for well over a decade. This article explains what was approved, what the trial actually found, and what the approval does and doesn't mean for patients.

A Cancer With Few Recent Wins

Gastric and gastroesophageal adenocarcinomas remain difficult to treat once advanced: roughly one in five metastatic cases is HER2-positive, and independent coverage of the trial notes that only about 5-7% of patients with this stage of disease survive five years. Trastuzumab (Herceptin) plus chemotherapy has been the first-line standard for HER2-positive disease for well over a decade, and until now no head-to-head Phase 3 trial had shown a novel HER2-targeted therapy actually beating it.

What the Trial Found

The FDA's approval rests on HERIZON-GEA-01, a Phase 3 trial that enrolled 914 patients across three arms: zanidatamab plus tislelizumab plus chemotherapy (302 patients), zanidatamab plus chemotherapy alone (304 patients), and trastuzumab plus chemotherapy as the control (308 patients). Patients were enrolled between December 2021 and February 2025, with a median follow-up of roughly two years.

The results, drawn directly from the FDA's own approval summary, are genuinely strong: patients on the triplet regimen reached a median overall survival of 26.4 months, compared with 19.2 months on trastuzumab plus chemotherapy (hazard ratio 0.72, p=0.0043) — a difference of more than seven months in a disease where survival is typically measured in months. Median progression-free survival followed the same pattern: 12.4 months versus 8.1 months (hazard ratio 0.63, p<0.0001). Independent trial coverage reports the benefit held up regardless of patients' PD-L1 status, and describes HERIZON-GEA-01 as the first Phase 3 trial to demonstrate that a novel HER2-targeted therapy can outperform trastuzumab in this setting — a meaningful milestone after years without one. Full results were published in the New England Journal of Medicine, and the trial remains ongoing, with additional analyses planned.

What the FDA Actually Approved

The FDA cleared two related regimens rather than a single one-size-fits-all treatment: zanidatamab combined with tislelizumab and chemotherapy for tumors with HER2 IHC 3+ or IHC 2+/ISH+ expression, and zanidatamab combined with chemotherapy alone for tumors with HER2 IHC 3+ expression. That distinction matters because the specific regimen a patient receives depends on how strongly their tumor expresses HER2, determined through pathology testing — not every HER2-positive patient will be a candidate for the same combination.

The Real Risks

This is not a low-risk treatment, and the FDA's labeling reflects that directly. Zanidatamab carries a boxed warning — the FDA's strongest warning category — for diarrhea and for harm to a developing fetus, along with additional warnings for declining heart function and infusion-related reactions. Tislelizumab, a PD-1 checkpoint inhibitor, carries its own warnings for immune-mediated adverse reactions, infusion reactions, complications related to allogeneic stem cell transplantation, and fetal harm. These are serious drugs for a serious, life-threatening disease, and patients considering this combination should discuss the specific risks with their oncology team in detail.

Bottom Line

This is a genuine, well-documented advance: a large, randomized Phase 3 trial found a new first-line combination extended median survival by more than seven months over a treatment that had gone unchallenged for over a decade, with the FDA formally approving it on the strength of that data on August 25, 2026. That's real, meaningful progress for patients with a historically difficult cancer. At the same time, this is not a cure — patients still progress on this regimen, it carries serious boxed warnings, and which exact combination a patient qualifies for depends on their tumor's specific HER2 expression level. Patients with newly diagnosed HER2-positive gastric, gastroesophageal junction, or esophageal cancer should ask their oncologist whether HER2 testing and this new combination are relevant to their case.